Sciencast Management LP Purchases 12,838 Shares of Zoetis Inc. $ZTS

Key Points

• Sciencast Management LP significantly increased its stake in Zoetis Inc. by 148.7%, acquiring an additional 12,838 shares, bringing its total ownership to 21,474 shares valued at approximately $3.54 million.
• Several institutional investors made strategic moves, including new positions by 1248 Management LLC and Saudi Central Bank, while Cornerstone Planning Group and others expanded their existing stakes.
• Analysts' ratings for Zoetis are mixed, with four maintaining a buy rating and others changing ratings to hold as the company reported Q2 earnings that surpassed expectations with $1.76 EPS.

Sciencast Management LP increased its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 148.7% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,474 shares of the company's stock after acquiring an additional 12,838 shares during the period. Sciencast Management LP's holdings in Zoetis were worth $3,536,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. 1248 Management LLC purchased a new position in Zoetis in the first quarter worth $27,000. Saudi Central Bank purchased a new position in Zoetis in the first quarter worth $29,000. Cornerstone Planning Group LLC grew its position in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after acquiring an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after acquiring an additional 120 shares in the last quarter. Finally, Sound Income Strategies LLC grew its position in Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after acquiring an additional 164 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and cut their price target for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and cut their price target for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Piper Sandler upped their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $202.43.

Zoetis Price Performance

Shares of Zoetis stock opened at $153.15 on Monday. The business has a 50 day moving average of $153.16 and a 200 day moving average of $157.73. The company has a market cap of $67.87 billion, a PE ratio of 26.36, a P/E/G ratio of 2.46 and a beta of 0.88. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.